___

• 1.Duley L: The global impact of pre-eclampsia and eclampsia: Semin Perinatol 2009, 33 (3); 130-7
• 2.Redman CWG, Jacobson Sl, Russell R: Hypertension in pregnancy in de Swiet’s Medical Disorders in Obstetric Practice (Raymond O Powrie, Michael F Greee, William Camannn eds) page 153-81, Fifth edition, 2010. McMillan Company, Singapore
• 3.Barış E, Mollahaliloğlu S, Aydın S: Healthcare in Turkey: from laggard to leader: BMJ 2011, 342, c 7456 doi 10.1136/bmj c 7456
• 4.WHO and UNICEF estimation of maternal mortality for 2000 and 2003 and 2010 maternal mortality projected by Turkish Ministry of Health
• 5.WHO Statistics, 2010
• 6.Centre for Maternal and Child Enquiries(CMACE): Saving Mother’s Lifes: reviewing maternal deaths to make motherhood safer:2006-08. The Eighth Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011; 118(Suppl. 1) 1:203
• 7.Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM The classification and diagnosis of hypertensive disorders of pregnancy: statement from the international society for the study of hypertension in pregnancy(ISSHP). Hypertens Foundation, 2011: (Charity No: 1037116).
• 8.National Collaborating Centre for Women’s and Children’s Health. Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy. National Institute for Health and Clinical Excellence Guideline 107. London: RCOG. August 2010. [www. guidance. nice.org.uk/CG107/]. Accessed 5 October 2010.
• 9.The Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002; 359: 1877-1890
• 10.The Eclampsia Trial Collaborative Group: Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet 1995; 345:1455-63
• 11.Baxter JK, Weinstein L: HELLP syndrome: the state of the art. Obstet Gynecol Surv 2004, 59:838-845.
• 12.Knight M, Nelson-Piercy C, Kurinczuk JJ, Spark P, Brocklehurst P. A prospective national study of acute fatty liver of pregnancy in the UK. Gut 2008;57:951–6
• 13.Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH.: Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn. 2011 Jan;31(1):66-74. doi: 10.1002/pd.2660
• 14.Akolekar R, Zaragoza E, Poon LCY, Pepes S, Nicolaides KH:. Maternal serum placental growth factor (PlGF) at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Ultrasound Obstet Gynecol 2008 32:732–739.
• 15.Akolekar R, Minekawa R, Veduta A, Romero XC, Nicolaides KH.. Maternal plasma inhibin A at 11 to 13 weeks of gestation in hypertensivedisorders of pregnancy. Prenat Diagn 2009a 29: 75 3–760.
• 16.Akolekar R, Etchegaray A, Zhou Y, Maiz N, Nicolaides KH. Maternal serum activin A at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Fetal Diagn Ther 2009b.25: 322–327.
• 17.Akolekar R, Casagrandi D, Livanos P, Tetteh A, Nicolaides KH. Maternal plasma pentraxin 3 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn2009c. 29: 934–938.
• 18.Akolekar R, Syngelaki A, Beta J, Kocylowski R, Nicolaides KH.. Maternal serum placental protein 13 at 11–13 weeks of gestation in preeclampsia. Prenat Diagn 2009d 29: 1103–1108.
• 19.Akolekar R, Veduta A, Minekawa R, Chelemen T, Nicolaides KH..Maternal plasma P-selectin at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Hypertens Pregnancy 2010 DOI: 10.3109/106419509032 42683.
• 20.Levine RJ, Lindheimer MD.. First-trimester prediction of early preeclampsia: a possibility at last! Hypertension 2009: 53: 747–748.
• 21.Foidart JM, Manuat C, Akolekar R, Cruz J, Nicolaides KH.. Maternal plasma soluble endoglin at 11–13 weeks of pregnancy in preeclampsia. Ultrasound Obstet Gynecol 35: 680–687.
• 22.Giguere Y, Charland M, Bujold E, et al. Combining biochemical and ultrasonographic markers in predicting preeclampsia: a system atic review.Clin Chem 2010 56: 361–374.
• 23.Plasencia W, Maiz N, Bonino S, Kaihura C, Nicolaides KH.. Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of preeclampsia. Ultrasound Obstet Gynecol 2007; 30: 742–749.
• 24.Poon LC, Kametas NA, Chelemen T, Leal A, Nicolaides KH.. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens 2010a 24: 104–110.
• 25.Poon LC, Kametas NA, Valencia C, Chelemen T, Nicolaides KH. Hypertensive disorders in pregnancy: screening by systolic diastolic and mean arterial pressure at 11–13 weeks. Hypertens Pregnancy 2010b DOI: 10.3109 / 10641955.2010.484086
• 26.Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a metaanalysis Obstet Gynecol 2010 116: 402–414.
• 27.Şen C: Management of Severe Pre-eclampsia and Eclampsia (Chapter 202) in Textbook of Perinatal Medicine(Asım Kurjak, Frank A Chervenak eds), pp 2688-97, Second Edition, Informa Healthcare, 2006, UK
• 28.McDonald SJ, Abbott JN, Higgins SP. Prophylactic ergometrineoxytocin versus oxytocin for the third stage of labour. Cochrane Database Syst Rev 2004;Issue 1:CD000201
• 29.Frederick U. Eruo and Baha M. Sibai : Hypertensive diseases in pregnancy in Clinical Obstetrics(E.Albert Reece, John C Hobbins eds) Clinical Obstetrics: The Fetus and Mother Blackwell Publishing Third Edition, Hong Kok, 683-99, 2007
• 30.Douglas KA, Redman CW. Eclampsia in the United Kingdom. BMJ 1994;309:1395–400.
• 31.Knight M. Eclampsia in the United Kingdom 2005. BJOG 2007;114:1072–8.
• 32.Sibai BM: Hypertensive Emergencies(chapter 5) in Obstetric Intensive Care Manual (Michael Foley, Thomas R Strong, Thomas J Garite eds), pp 49-60, McGraw Hill, New York 2011